(-0.02%) 5 468.46 points
(0.00%) 39 112 points
(0.27%) 17 766 points
(-0.25%) $80.63
(-5.04%) $2.62
(-0.91%) $2 309.70
(-0.39%) $28.76
(3.07%) $1 016.70
(0.36%) $0.937
(0.75%) $10.68
(0.53%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease...
Stats | |
---|---|
Dagens volum | 34 640 |
Gjennomsnittsvolum | 120 593 |
Markedsverdi | 56.22M |
EPS | $-0.300 ( Q1 | 2024-05-14 ) |
Neste inntjeningsdato | ( $-0.310 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.600 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0150 (1.63%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-21 | Countouriotis Athena | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Gowen Maxine | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Kapadia Sandip | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Islam Saqib | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Sondhi Dolan | Buy | 39 092 | Director Stock Option (right to buy) |
INSIDER POWER |
---|
82.54 |
Last 97 transactions |
Buy: 8 193 316 | Sell: 441 732 |
Volum Korrelasjon
Passage Bio Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
REYN | 0.88 |
POWL | 0.873 |
VEON | 0.861 |
CLBT | 0.86 |
CFLT | 0.854 |
MRUS | 0.851 |
FWRG | 0.846 |
EQ | 0.842 |
MEDP | 0.837 |
MACK | 0.835 |
10 Mest negative korrelasjoner | |
---|---|
CYAN | -0.857 |
CAR | -0.831 |
WTER | -0.829 |
SSRM | -0.829 |
FINW | -0.827 |
BIOL | -0.826 |
EGAN | -0.821 |
KRKR | -0.818 |
VREX | -0.813 |
BLKB | -0.809 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Passage Bio Inc Korrelasjon - Valuta/Råvare
Passage Bio Inc Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-3.68M (0.00 %) |
EPS: | $-2.51 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-3.48 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.